Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.

Genenta Science S.p.A.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MILAN AND NAPLES, ITALY, JULY 23, 2026 (GLOBE NEWSWIRE) -- SPHIA HIGH TECH S.R.L. (SPHIA HT), AN ITALIAN AEROSPACE AND DEFENSE COMPANY MANUFACTURING CRITICAL PARTS FOR EUROPE'S SPACE AND DEFENSE PROGRAMS, BACKED BY GENENTA SCIENCE S.P.A.

GENENTA-BACKED SPHIA HIGH TECH BRINGS AEROSPACE PRECISION INSIDE A NUCLEAR FUSION REACTOR WITH ROMAN, A ROBOTIC ARM

FISCAL YEAR 2025 HIGHLIGHTS FY2025 SALES ROSE 29.3% TO 7.17 MILLION; TOTAL VALUE OF PRODUCTION INCREASED 34.7% TO 8.47 MILLION EBITDA GREW 68.1% TO 1.61 MILLION, EXPANDING THE EBITDA MARGIN BY APPROXIMATELY 380 BASIS POINTS TO 19.0% OPERATING PROFIT ADVANCED 80.8% TO 1.21 MILLION MILAN, JULY 22, 2026 (GLOBE NEWSWIRE) -- GENENTA SCIENCE S.P.A. (NASDAQ: GNTA), EVOLVING INTO SAENTRA FORGE1, A STRATEGIC INDUSTRIAL CONSOLIDATOR FOCUSED ON AEROSPACE, DEFENSE, BIOTECH AND ITALIAN NATIONAL-SECURITY-RELATED TECHNOLOGIES, TODAY ANNOUNCED THAT THE BOARD OF DIRECTORS OF SPHIA HIGH TECH S.R.L.

GENENTA-BACKED SPHIA HIGH TECH REPORTS FISCAL YEAR 2025 RESULTS

GENENTA SIGNS DEFINITIVE AGREEMENTS WITH SOPHIA HIGH TECH GENENTA ENTERS AEROSPACE AS IT CONTINUES ITS STRATEGIC TRANSFORMATION INTO A NEXT-GENERATION IND

GENENTA SIGNS DEFINITIVE AGREEMENTS WITH SOPHIA HIGH TECH

MILAN, MARCH 27, 2026 (GLOBE NEWSWIRE) -- GENENTA SCIENCE S.P.A. (NASDAQ: GNTA), EVOLVING INTO SAENTRA FORGE1, A STRATEGIC INDUSTRIAL CONSOLIDATOR FOCUSED ON BIOTECH, DEFENSE, AEROSPACE, AND ITALIAN NATIONAL-SECURITY-RELATED TECHNOLOGIES, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A BINDING OFFER WITH SPHIA HIGH TECH S.R.L.

GENENTA, EVOLVING INTO SAENTRA FORGE, HAS SIGNED A BINDING OFFER WITH SPHIA HIGH TECH, AN ITALIAN COMPANY MANUFACTURING CRITICAL PARTS FOR EUROPE'S SPACE AND DEFENSE PROGRAMS

FOCUSED ON SELECTIVE ACQUISITIONS OF HIGH-QUALITY COMPANIES IN STRATEGIC INDUSTRIAL SECTORS FOCUSED ON SELECTIVE ACQUISITIONS OF HIGH-QUALITY COMPANIES IN STRATEGIC INDUSTRIAL SECTORS

GENENTA, EVOLVING INTO SAENTRA FORGE, CONTINUES TO EVALUATE STRATEGIC OPTIONS FOR ITS ORIGINAL BIOTECHNOLOGY PLATFORM DERIVED FROM THE RESEARCH OF PROFESSOR LUIGI NALDINI

MILAN, MARCH 13, 2026 (GLOBE NEWSWIRE) -- GENENTA SCIENCE S.P.A. (NASDAQ: GNTA) TRANSFORMING TO SAENTRA FORGE (NASDAQ: SAEN)1, A STRATEGIC INDUSTRIAL CONSOLIDATOR FOCUSED ON BIOTECH, DEFENSE, AEROSPACE, AND ITALIAN NATIONAL-SECURITY-RELATED TECHNOLOGIES, TODAY ANNOUNCED THAT PIERLUIGI PARACCHI, CEO OF THE COMPANY, HAS BEEN APPOINTED AS A MEMBER OF THE BOARD OF GUARANTORS OF THE ITALIAN ACADEMY FOR ADVANCED STUDIES IN AMERICA, THE PRESTIGIOUS CENTER FOR ADVANCED SCHOLARSHIP HOSTED AT COLUMBIA UNIVERSITY IN NEW YORK, DEDICATED TO PROMOTING ITALIAN CULTURE, RESEARCH, AND INTELLECTUAL EXCHANGE BETWEEN ITALY AND THE UNITED STATES.

GENENTA, EVOLVING INTO SAENTRA FORGE, ANNOUNCES CEO'S APPOINTMENT BY THE ITALIAN GOVERNMENT TO THE BOARD OF GUARANTORS OF THE ITALIAN ACADEMY AT COLUMBIA UNIVERSITY

MILAN, FEB. 27, 2026 (GLOBE NEWSWIRE) -- GENENTA SCIENCE S.P.A. (NASDAQ: GNTA) IN TRANSFORMATION TO SAENTRA FORGE (NASDAQ: SAEN), A STRATEGIC INDUSTRIAL CONSOLIDATOR FOCUSED ON BIOTECH, DEFENSE, AEROSPACE, AND NATIONAL-SECURITY-RELATED TECHNOLOGIES, TODAY ANNOUNCED THE APPOINTMENT OFPAOLO SALVATO TO THE BOARD OF DIRECTORS OF ATC, A MANUFACTURER OF TACTICAL DEFENSE SYSTEMS REPRESENTING THE COMPANY'S INITIAL ENTRY INTO DEFENSE TECHNOLOGY MANUFACTURING.

GENENTA ADVANCES TRANSFORMATION INTO SAENTRA FORGE, STRENGTHENS ATC GOVERNANCE AND EXPANDS STRATEGIC INDUSTRIAL CONSOLIDATION PLATFORM

BUILDING ON BIOTECH HERITAGE, EXPANDING INTO DEFENSE AND NATIONAL SECURITY THROUGH INDUSTRIAL INTEGRATIONS OF PRIVATELY HELD SPECIALIZED ITALIAN COMPANIES ATC - A DEFENSE-SECTOR COMPANY: FIRST INDUSTRIAL INTEGRATION PRAEXIDIA FOUNDATION JOINS AS A LONG-TERM STRATEGIC SHAREHOLDER CORPORATE NAME CHANGE TO SAENTRA FORGE S.P.A. BIOTECH CLINICAL UPDATES AND PARTNERING STRATEGY CASH,  CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF APPROX.

GENENTA ANNOUNCES STRATEGIC TRANSFORMATION INTO A BIOTECH, DEFENSE, AEROSPACE, AND NATIONAL SECURITY INDUSTRIAL CONSOLIDATOR

MILAN AND NEW YORK, DEC. 19, 2025 (GLOBE NEWSWIRE) -- GENENTA SCIENCE (NASDAQ: GNTA), A CLINICAL-STAGE GENE-THERAPY COMPANY DEVELOPING HEMATOPOIETIC STEM-CELL-BASED IMMUNOTHERAPIES FOR SOLID TUMORS, PROVIDES AN UPDATE REGARDING THE OWNERSHIP POSITION OF ITS CHIEF EXECUTIVE OFFICER AND CO-FOUNDER, PIERLUIGI PARACCHI. OVER TIME, MR.

GENENTA SCIENCE PROVIDES UPDATE ON CEO OWNERSHIP

MILAN, ITALY AND NEW YORK, NOV. 24, 2025 (GLOBE NEWSWIRE) -- GENENTA SCIENCE (NASDAQ: GNTA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING A CELL-BASED PLATFORM FOR TARGETED DELIVERY OF THERAPEUTIC PAYLOADS IN ONCOLOGY, TODAY ANNOUNCED ANUPDATE FROM ITS ONGOING TEM-GBM STUDY IN NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) PATIENTS WITH AN UNMETHYLATED MGMT (UMGMT) GENE PROMOTER. AS OF THENOVEMBER 21, 2025DATA CUT,25 PATIENTSHAVE BEEN TREATED WITH TEMFERON.

Genenta Science S.p.A.

GNTA

Price

Financial Reports

No items found.

Press Releases

Genenta Science S.p.A.

GNTA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

GNTA